FDA Adverse Event Injury Summary report: N

ZIMMER M/L TAPER FEMORAL STEM

MDR report key: 3201659 · Received June 28, 2013

Report

Report Number
1822565-2013-01042
Event Type
Injury
Date Received
June 28, 2013
Date of Event
December 15, 2010
Report Date
May 31, 2013
Manufacturer
ZIMMER, INC.
Product Code
KWA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

INFORMATION WAS RECEIVED FROM A CONSUMER WHO IS NOT REQUIRED TO COMPLETE FORM 3500A. EVALUATION SUMMARY: PRIMARY OPERATIVE NOTES HAVE BEEN RETURNED WHICH WERE UNREMARKABLE. THE PT WAS IMPLANTED WITH METAL-ON-METAL COMPONENTS. REVISION NOTES WERE PROVIDED WHICH NOTE THAT THE SURGEON BELIEVED THE PT WAS HAVING PAIN BECAUSE OF FIBROUS INGROWTH OF THE FEMORAL PROSTHESIS SECONDARY TO IMPAIRED VASCULAR SUPPLY IN THE EARLY POSTOPERATIVE PERIOD. THE STEM SHOWED NO POSTERIOR BONE ONGROWTH, PATCHY BONE ONGROWTH ANTERIORLY, AND SOME BONY ONGROWTH ALONG THE CALCAR PORTION OF THE STEM. DURING REMOVAL OF THE STEM WITH A SLAP HAMMER AN INCOMPLETE CRACK DEVELOPED IN THE CALCAR WHICH WAS TREATED BY PASSING TWO CIRCUMFERENTIAL CABLES AROUND THE PROXIMAL FEMUR. A CEMENTED FEMORAL COMPONENT WAS THEN IMPLANTED. FROM THE INFO PROVIDED, A DEFINITIVE CAUSE CANNOT BE DETERMINED. REVIEW OF THE DEVICE HISTORY RECORDS WAS NOT POSSIBLE AS THE PRODUCT AND/OR LOT NUMBERS REQUIRED FOR RETRIEVAL WERE UNAVAILABLE. IT IS NOT SUSPECTED THAT THE PRODUCT FAILED TO MEET SPECIFICATIONS. THE INVESTIGATION COULD NOT VERIFY OR IDENTIFY ANY EVIDENCE OF PRODUCT CONTRIBUTION TO THE REPORTED PROBLEM. BASED ON THE AVAILABLE INFO, THE NEED FOR CORRECTIVE ACTION IS NOT INDICATED. SHOULD ADD'L SUBSTANTIVE INFO BE REC'D, THE COMPLAINT WILL BE REOPENED. ZIMMER, INC CONSIDERS THE INVESTIGATION CLOSED.

Description of Event or Problem · 1

IT IS REPORTED THAT THE PT WAS REVISED DUE TO FIBROUS INGROWTH.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
296778 ZIMMER M/L TAPER FEMORAL STEM KWA ZIMMER, INC. 61172397

Patients

Seq Age Sex Outcome Treatment
1 68 YR Required Intervention